Beijing Winsunny Pharmaceutical CO.LTD - Asset Resilience Ratio
Beijing Winsunny Pharmaceutical CO.LTD (601089) has an Asset Resilience Ratio of 10.89% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 601089 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Beijing Winsunny Pharmaceutical CO.LTD's Asset Resilience Ratio has changed over time. See 601089 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Beijing Winsunny Pharmaceutical CO.LTD's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Beijing Winsunny Pharmaceutical CO.LTD market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥511.00 Million | 10.89% |
| Total Liquid Assets | CN¥511.00 Million | 10.89% |
Asset Resilience Insights
- Moderate Liquidity: Beijing Winsunny Pharmaceutical CO.LTD has 10.89% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Beijing Winsunny Pharmaceutical CO.LTD Industry Peers by Asset Resilience Ratio
Compare Beijing Winsunny Pharmaceutical CO.LTD's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Beijing Winsunny Pharmaceutical CO.LTD (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Beijing Winsunny Pharmaceutical CO.LTD.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 32.78% | CN¥1.58 Billion ≈ $231.06 Million |
CN¥4.82 Billion ≈ $704.82 Million |
+28.14pp |
| 2021-12-31 | 4.64% | CN¥100.00 Million ≈ $14.63 Million |
CN¥2.15 Billion ≈ $315.08 Million |
+1.73pp |
| 2020-12-31 | 2.91% | CN¥50.00 Million ≈ $7.32 Million |
CN¥1.72 Billion ≈ $251.21 Million |
-- |
About Beijing Winsunny Pharmaceutical CO.LTD
Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical preparations and medical devices China and internationally. The company provides chemical drugs and traditional chinese medicines. Its products used in cardiovascular kind, chronic kidney disease, skin disease, digestive system, diabetes, neuropsychiatric system kind, mental nervous system… Read more